Guerbet

61 articles about Guerbet

• Guerbet to Spotlight Diagnostic and Interventional Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting

  11/2/2023

  Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced its schedule of activities at the 2023 Radiological Society of North America Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL.

• Guerbet: First-half 2023 revenue

  7/20/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, is reporting its revenue for the first half of 2023.

• Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer

  7/17/2023

  Guerbet is delighted to announce the success of its teams at the PI-CAI Grand Challenge1, an international challenge organised by a consortium2 of radiology opinion leaders in prostate imaging, urologists and artificial intelligence experts, to compare the performance of artificial intelligence algorithms in the detection of prostate cancer.

• Guerbet: 2022 annual results

  3/22/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated financial statements for the 2022 fiscal year.

• Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem™ (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging (MRI)

  2/13/2023

  Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022.

• Guerbet: 2022 revenue

  2/9/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, has reported its annual revenue.

• Guerbet: 2023 Strategic Priorities

  1/16/2023

  Guerbet, a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

• Guerbet: Revenue at September 30, 2022

  10/20/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reported its revenue for the first 9 months of 2022.

• Guerbet: 2022 half-year results

  9/21/2022

  Villepinte, Wednesday, September 21, 2022: Guerbet, a global specialist in contrast agents and solutions for medical imaging, is announcing its consolidated results for the first half of 2022.

• Guerbet: Revenue at June 30, 2022

  7/21/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reports its revenue for the first half of 2022.

• Guerbet: Q1 2022 revenue

  4/21/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reports its revenue for first-quarter 2022.

• Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA

  3/29/2022

  Guerbet has recently submitted a New Drug Application to the U.S. Food and Drug Administration and a Centralized Application for Marketing Authorization to the European Medicine Agency for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent.

• Guerbet: 2021 annual results

  3/23/2022

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, is announcing its consolidated annual results for 2021.

• Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

  12/14/2021

  Guerbet and Bracco Imaging announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging contrast agent.

• Guerbet: Revenue at September 30, 2021

  10/21/2021

  Guerbet, a global specialist in contrast agents and solutions for medical imaging, reported its sales for the first nine months of the year.

• 

  BioSpace Movers & Shakers, June 4

  6/4/2021

  Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.

• Guerbet to Showcase its UNIK Solution at RSNA 2020

  11/12/2020

  Guerbet a global leader in medical imaging, announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America.

• 

  BioSpace Global Roundup, June 18

  6/18/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
• 

  BioSpace Global Roundup, May 21

  5/21/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.